These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28750917)

  • 1. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
    Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
    Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
    Chuaypen N; Sriprapun M; Praianantathavorn K; Payungporn S; Wisedopas N; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2017 Jan; 89(1):130-138. PubMed ID: 27307409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
    Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
    Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
    Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
    J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA.
    Chen EQ; Wang ML; Tao YC; Wu DB; Liao J; He M; Tang H
    J Viral Hepat; 2019 May; 26(5):586-595. PubMed ID: 30632235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B.
    Beudeker BJ; Groothuismink ZM; de Man RA; Janssen H; van der Eijk AA; Boonstra A; Sonneveld MJ
    Antivir Ther; 2020; 25(4):217-222. PubMed ID: 32744512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
    Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
    Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
    Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
    Aliment Pharmacol Ther; 2018 Jan; 47(1):43-54. PubMed ID: 29035003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.
    Suzuki F; Miyakoshi H; Kobayashi M; Kumada H
    J Med Virol; 2009 Jan; 81(1):27-33. PubMed ID: 19031469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
    Farag MS; van Campenhout MJH; Pfefferkorn M; Fischer J; Deichsel D; Boonstra A; van Vuuren AJ; Ferenci P; Feld JJ; Berg T; Hansen BE; van Bömmel F; Janssen HLA
    Clin Infect Dis; 2021 Jan; 72(2):202-211. PubMed ID: 31912157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    Martinot-Peignoux M; Lapalus M; Maylin S; Boyer N; Castelnau C; Giuily N; Pouteau M; Moucari R; Asselah T; Marcellin P
    J Viral Hepat; 2016 Nov; 23(11):905-911. PubMed ID: 27375231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
    Matsumoto A; Nishiguchi S; Enomoto H; Kang JH; Tanaka Y; Shinkai N; Kurosaki M; Enomoto M; Kanda T; Yokosuka O; Yatsuhashi H; Nagaoka S; Okuse C; Kagawa T; Mine T; Takaguchi K; Saito S; Hino K; Ikeda F; Sakisaka S; Morihara D; Miyase S; Tsuge M; Chayama K; Hiramatsu N; Suzuki Y; Murata K; Tanaka E
    J Gastroenterol; 2018 Feb; 53(2):247-257. PubMed ID: 28634723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.